---
title: "Esperion Settles Patent Litigation With Micro Labs For Generic Nexletol"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/239864623.md"
description: "Esperion Therapeutics, Inc. (ESPR) has settled patent litigation with Micro Labs USA, Inc. and Micro Labs Ltd., preventing the marketing of a generic version of Nexletol in the U.S. until April 19, 2040. This settlement follows Esperion's lawsuit against Micro Labs for filing an Abbreviated New Drug Application for a generic version before patent expiration. Esperion continues litigation against other defendants including Accord Healthcare and Dr. Reddy's Laboratories."
datetime: "2025-05-12T14:02:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/239864623.md)
  - [en](https://longbridge.com/en/news/239864623.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/239864623.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/239864623.md) | [English](https://longbridge.com/en/news/239864623.md)


# Esperion Settles Patent Litigation With Micro Labs For Generic Nexletol

Esperion Therapeutics, Inc. (ESPR) Monday announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Ltd. to resolve a patent litigation. As per the agreement, Micro Labs has agreed not to  
market a generic version of Nexletol in the United States prior to April 19, 2040.

Esperion, a commercial stage biopharmaceutical company, has earlier filed a patent infringement lawsuit against the Micro Labs. The litigation was in response to Micro Labs' filing of Abbreviated New Drug Application seeking approval to market a generic version of Nexletol, prior to the expiration of the applicable patents.

Esperiod has ongoing patent litigation against the remaining defendants Accord Healthcare Inc; Alkem Laboratories Ltd.; Aurobindo Pharma Limited, Dr. Reddys Laboratories Inc., Hetero USA Inc., MSN Pharmaceuticals Inc., Renata Ltd. and Sandoz Inc.

For comments and feedback contact: editorial@rttnews.com

Business News

### 相關股票

- [Esperion Therap (ESPR.US)](https://longbridge.com/zh-HK/quote/ESPR.US.md)

## 相關資訊與研究

- [Esperion Insiders Quietly Cash Out as Top Executives Trim Their Stakes](https://longbridge.com/zh-HK/news/279718023.md)
- [Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference](https://longbridge.com/zh-HK/news/279175638.md)
- [Esperion Therapeutics Q4 Earnings Call Highlights](https://longbridge.com/zh-HK/news/278573800.md)
- [Esperion Therapeutics Grants 40,200 Inducement RSUs to New Employees](https://longbridge.com/zh-HK/news/275660752.md)
- [FDA untitled letter skewers Esperion’s Nexlizet TV ad](https://longbridge.com/zh-HK/news/271820920.md)